Actinogen Medical Limited · ASX:ACW
Actinogen Medical — Investor Presentation (September 2020)
16 slides from Actinogen Medical's investor presentation, Sep 9, 2020
Slide 1: ASX Announcement: Actinogen Medical Investor Presentation
ASX ANNOUNCEMENT Actinogen Medical Investor Presentation For personal use only Sydney, 9 September 2020. Actinogen Medical ASX: ACW (‘ACW’ or ‘the Company’) is pleased to release an updated Investor Presentation. This presentation will be used to update existing shareholders, potential investors, st
Slide 2: About Xanamem
About Xanamem™ Xanamem’s novel mechanism of action sets it apart from currently available therapies. It works by blocking the production of intracellular cortisol – the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. There is a strong association between persistent stres
Slide 3: Investor Presentation
For personal use only Investor Presentation Dr. Bill Ketelbey: CEO & MD September 2020 Developing innovative treatments for cognitive impairment associated with neurological and metabolic diseases due to raised cortisol, including Alzheimer’s disease
Slide 4: Xanamem – lead compound
Xanamem™ – lead compound A novel mechanism of action designed to inhibit cortisol production in the brain (via 11β-HSD1 inhibition) For personal use only Novel MoA (cortisol inhibition) PoC demonstrated in animal trials PoC demonstrated in human trials Strong safety profile Excellent PK/PD profile X
Slide 5: Strategic focus underpinned by significant medical research
Strategic focus underpinned by significant medical research A growing body of medical literature supports the association between chronically raised cortisol, cognitive impairment and lower brain volumes For personal use only Raised cortisol associated with Alzheimer’s disease1 Supported by growing
Slide 6: Highlights: Demonstration of Xanamem's promising efficacy and safety
Highlights: Demonstration of Xanamem’s promising efficacy and safety A significantly enhanced and growing dataset For personal use only Target Occupancy Comprehensive & Homogenate Data Analysis Binding studies Efficacy shown in Phase 1 Phase 2 clinical trial in mild QSP1 and PK/PD2 modelling Phase 1
Slide 7: Significant cognitive efficacy signal achieved
Significant cognitive efficacy signal achieved Breakthrough results from Cogstate Cognitive Test Battery evaluation demonstrate robust statistically significant cognitive efficacy improvement in multiple domains with a rapid and sustained response For personal use only Working memory (One Back Test)
Slide 8: Target Occupancy study: positive confirmatory data
Target Occupancy study: positive confirmatory data Phase I target occupancy study demonstrates that 5mg to 30mg Xanamem dosed for seven days significantly occupies the neuronal 11β-HSD1 enzyme throughout the brain (32 of 36 patients completed) For personal use only 50% to 85% occupancy, dependent up
Slide 9: Key outcomes from Xanamem studies
Key outcomes from Xanamem studies Xanamem dose For personal use only Cognitive Breakthrough results demonstrate a statistically significant clinical effect 20mg Efficacy in improving cognition in healthy elderly patients Target Confirms Xanamem works as designed to penetrate the brain in 5mg - 30mg
Slide 10: Detailed data analysis completed
Detailed data analysis completed Quantitative Systems Pharmacology modelling and analysis For personal use only Genetic Human information pathology, Analysis of entire dataset completed clinical data Human Conclusions will be used to optimise physiology dyi parameters for next series of clinical = f
Slide 11: Strategic direction and next steps
Strategic direction and next steps Updated clinical development plan incorporating new Xanamem data supporting clinical development opportunities across multiple indications For personal use only Enhanced clinical development strategy Next steps (in progress) (near future) Comprehensive review of al
Slide 12: Next series of Xanamem studies
Next series of Xanamem studies Actinogen leveraging Xanamem development across multiple target indications For personal use only Alzheimer’s disease (MCI due to AD) Xanamem Schizophrenia1 Diabetes2 Ongoing assessment of new opportunities as they arise Other 1. Cognitive impairment associated with Sc
Slide 13: Alzheimer's disease focus
Alzheimer’s disease focus Actinogen plans to target patients with Mild Cognitive Impairment due to AD (an early stage of the AD spectrum) as part of the next phase of studies, linking the XanaHES results with Alzheimer’s disease For personal use only Healthy elderly Mild Moderate Severe Mild Cogniti
Slide 14: Market dynamics of Alzheimer's disease
Market dynamics of Alzheimer’s disease Early stage AD presents a compelling commercial opportunity for Actinogen to target For personal use only High prevalence resulting in substantial target market1 Underpinned by favourable market dynamics Subjective Cognitively Cognitive and functional decline n
Slide 15: Investment summary
Investment summary Actinogen is developing Xanamem as a potential treatment for cognitive impairment associated with raised cortisol in a range of diseases, with a primary focus on Alzheimer’s disease For personal use only Xanamem – a differentiated compound with a validated novel MoA and strong s
Slide 16: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all inform
Actinogen Medical — Investor Presentation (September 2020) on 6ix